Opioids are under the microscope by a variety of groups, including political and pharmaceutical organizations. Now, adding fuel to the fire is a recent agreement between Pfizer and the City of Chicago. What does such an unprecedented deal mean for the industry? This article lays out the recent actions taken in connection with opioids and what they may mean for the industry.
Unless you are not following the news, it is hard to miss all the scrutiny being given to opioids in recent months. The increased scrutiny is the result of heightened concerns in that the United States is facing: more overdoses, higher rates of addiction, and prescription cost increases that outstrip the cost of inflation. Given that it is an election year, it is not surprising that so many political and advocacy groups are involved.
Read Full Article in the October 2016 Issue of Life Science Compliance Update